Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Visine A.C. is an over-the-counter ophthalmic solution developed and marketed by Kenvue. It is a combination product containing two active ingredients: tetrahydrozoline hydrochloride, a small molecule alpha-1 adrenergic receptor agonist, and zinc sulfate, an astringent. Tetrahydrozoline acts as a vasoconstrictor by constricting the superficial blood vessels in the conjunctiva, thereby temporarily reducing eye redness. Zinc sulfate functions as an astringent to help relieve irritation and clear mucus from the outer surface of the eye. This combination is indicated for the temporary relief of discomfort and redness due to minor eye irritations, including symptoms such as itchy, red, and watery eyes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Visine A.C..